134 related articles for article (PubMed ID: 24634242)
1. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.
Xu J; Ma J; Zong HT; Wang SY; Zhou JW
Genet Mol Res; 2014 Mar; 13(1):1438-46. PubMed ID: 24634242
[TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.
Cao Z; Song J; Wang J; Guo X; Yu S; Dong W
PLoS One; 2014; 9(1):e85357. PubMed ID: 24465544
[TBL] [Abstract][Full Text] [Related]
3. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.
Wu H; Xu C; Chen G; Wang J
J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851
[TBL] [Abstract][Full Text] [Related]
4. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
6. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.
Zhang X; Jiang LP; Yin Y; Wang YD
Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.
Li L; Wan C; Wen FQ
Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464
[TBL] [Abstract][Full Text] [Related]
8. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis.
Xue H; Ni P; Lin B; Xu H; Huang G
Am J Epidemiol; 2011 Feb; 173(4):363-75. PubMed ID: 21216841
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
10. Effect of X-ray repair cross complementing group 1 polymorphisms on the efficacy of platinum-based chemotherapy in patients with nonsmall cell lung cancer.
Fan X; Xiu Q
J Cancer Res Ther; 2015; 11(3):571-4. PubMed ID: 26458583
[TBL] [Abstract][Full Text] [Related]
11. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
12. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
14. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.
Zhang Z; Xiang Q; Mu G; Xie Q; Chen S; Zhou S; Hu K; Cui YM
Medicine (Baltimore); 2018 Nov; 97(45):e12996. PubMed ID: 30407287
[TBL] [Abstract][Full Text] [Related]
15. XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis.
Shuai HL; Luo X; Yan RL; Li J; Chen DL
Asian Pac J Cancer Prev; 2012; 13(12):6423-7. PubMed ID: 23464469
[TBL] [Abstract][Full Text] [Related]
16. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract][Full Text] [Related]
17. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
18. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Liu YP; Ling Y; Zhang YP; Liu BR
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
20. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
